Literature DB >> 10797245

Purification of a cystic fibrosis plasmid vector for gene therapy using hydrophobic interaction chromatography.

M M Diogo1, J A Queiroz, G A Monteiro, S A Martins, G N Ferreira, D M Prazeres.   

Abstract

The success and validity of gene therapy and DNA vaccination in in vivo experiments and human clinical trials depend on the ability to produce large amounts of plasmid DNA according to defined specifications. A new method is described for the purification of a cystic fibrosis plasmid vector (pCF1-CFTR) of clinical grade, which includes an ammonium sulfate precipitation followed by hydrophobic interaction chromatography (HIC) using a Sepharose gel derivatized with 1,4-butanediol-diglycidylether. The use of HIC took advantage of the more hydrophobic character of single-stranded nucleic acid impurities as compared with double-stranded plasmid DNA. RNA, denatured genomic and plasmid DNAs, with large stretches of single strands, and lipopolysaccharides (LPS) that are more hydrophobic than supercoiled plasmid, were retained and separated from nonbinding plasmid DNA in a 14-cm HIC column. Anion-exchange HPLC analysis proved that >70% of the loaded plasmid was recovered after HIC. RNA and denatured plasmid in the final plasmid preparation were undetectable by agarose electrophoresis. Other impurities, such as host genomic DNA and LPS, were reduced to residual values with the HIC column (<6 ng/microg pDNA and 0.048 EU/microg pDNA, respectively). The total reduction in LPS load in the combined ammonium acetate precipitation and HIC was 400,000-fold. Host proteins were not detected in the final preparation by bicinchoninic acid (BCA) assay and sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) with silver staining. Plasmid identity was confirmed by restriction analysis and biological activity by transformation experiments. The process presented constitutes an advance over existing methodologies, is scaleable, and meets quality standards because it does not require the use of additives that usually pose a challenge to validation and raise regulatory concerns. Copyright 2000 John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10797245

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  6 in total

1.  On the stability of plasmid DNA vectors during cell culture and purification.

Authors:  S S Freitas; A R Azzoni; J A L Santos; G A Monteiro; D M F Prazeres
Journal:  Mol Biotechnol       Date:  2007-06       Impact factor: 2.695

2.  Separation of supercoiled from open circular forms of plasmid DNA, and biological activity detection.

Authors:  Huangjin Li; Huaben Bo; Jinquan Wang; Hongwei Shao; Shulin Huang
Journal:  Cytotechnology       Date:  2010-12-01       Impact factor: 2.058

3.  Good Manufacturing Practices production and analysis of a DNA vaccine against dental caries.

Authors:  Ya-ping Yang; Yu-hong Li; Ai-hua Zhang; Lan Bi; Ming-wen Fan
Journal:  Acta Pharmacol Sin       Date:  2009-11       Impact factor: 6.150

4.  Trans-sialidase from Trypanosoma brucei as a potential target for DNA vaccine development against African trypanosomiasis.

Authors:  Marcelo Sousa Silva; Duarte Miguel F Prazeres; Andreia Lança; Jorge Atouguia; Gabriel Amaro Monteiro
Journal:  Parasitol Res       Date:  2009-07-07       Impact factor: 2.289

Review 5.  Microbial lipases and their industrial applications: a comprehensive review.

Authors:  Prem Chandra; Ranjan Singh; Pankaj Kumar Arora
Journal:  Microb Cell Fact       Date:  2020-08-26       Impact factor: 5.328

6.  Synthesis and Characterization of Mannosylated Formulations to Deliver a Minicircle DNA Vaccine.

Authors:  Ana Sofia Serra; Dalinda Eusébio; Ana Raquel Neves; Tânia Albuquerque; Himanshu Bhatt; Swati Biswas; Diana Costa; Ângela Sousa
Journal:  Pharmaceutics       Date:  2021-05-07       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.